Doctors want it. Patients prefer it. Big Pharma needs it.
| On Behalf of BioNxt Solutions Inc. | | Dear Reader,
For decades medicine has meant two choices. A pill that often wastes much of the dose. Or a needle that patients hate.
But imagine a wafer-thin strip that melts on the tongue in seconds. No swallow. No injection. No fear.
This delivery format is designed for rapid absorption through the mouth, bypassing the gut and reducing first-pass loss. That means faster onset and more of the drug actually reaching the bloodstream.
The opportunity is staggering. Merck's Mavenclad is a billion-dollar seller. AbbVie's Humira peaked at $20 billion a year before its patent expired in 2023, wiping out billions in revenue almost overnight. Novartis lost 70% of Gleevec's $5 billion sales when its patent ended.
This small biotech has the patent play Big Pharma missed. Their cladribine strip is protected into the 2040s. At the same time they are advancing thin film programs for autoimmune disease, diabetes, obesity, and even cancer care.
Billions in annual markets. Patents stretching decades. Trials designed to deliver results in weeks, not years.
This is why we call it our number one penny stock biotech alert.
Get our full report now and unlock the complete analysis.
*Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities. |
|
| | | This is a PAID ADVERTISEMENT provided to subscribers of DividendBrief.Net. Although we have sent you this email, DividendBrief.Net does NOT specifically endorse this product nor is it responsible for the content of this advertisement. Furthermore, we make no guarantee or warranty about what is advertised above. | |
|
|
|
|
